File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/dmrr.255
- Scopus: eid_2-s2.0-0036200330
- PMID: 11921421
- WOS: WOS:000174502000010
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria
Title | Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria |
---|---|
Authors | |
Keywords | Angiotensin II receptor antagonist Diabetes mellitus Endothelial dysfunction Microalbuminuria |
Issue Date | 2002 |
Publisher | John Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/10009394 |
Citation | Diabetes/Metabolism Research And Reviews, 2002, v. 18 n. 1, p. 71-76 How to Cite? |
Abstract | Background. Microalbuminuria is associated with dysfunction of the vascular endothelium in patients with diabetes mellitus. The objective of the present study was to determine whether treatment with losartan at a dose sufficient to lower urinary albumin excretion was accompanied by an improvement in endothelial function in type 2 diabetic patients with microalbuminuria. Methods. Endothelial function was measured in 80 type 2 diabetic patients with microalbuminuria and 68 non-diabetic controls using high-resolution vascular ultrasound. The diabetic patients were randomised to receive either losartan 50 mg daily or placebo in a 6-month double-blind study. Urinary albumin excretion and endothelial function were assessed at baseline, 3 and 6 months. Results. Both endothelium-dependent (p < 0.01) and -independent vasodilation (p < 0.01) were significantly impaired in diabetic patients with or without history of hypertension compared to the non-diabetic controls. At baseline, the losartan- and placebo-treated groups were comparable in their clinical characteristics. Blood pressure did not change significantly in either group throughout the study. Urinary mean albumin excretion rate (MAER) decreased in the losartan-treated group (p < 0.01) whereas an increase was observed in the placebo group (p < 0.05). At 6 months, the losartan-treated group had significantly lower MAER than the placebo-treated group [54.5 (58.3) vs 78.5 (100.5) μg/min, p < 0.05; median (interquartile range)]. No significant differences were found in endothelium-dependent or -independent vasodilation. Conclusions. Type 2 diabetic patients with microalbuminuria have impaired endothelium-dependent and -independent vasodilation. Treatment with low-dose losartan is sufficient to reduce microalbuminuria in these patients without alteration in endothelial function and systemic blood pressure. Copyright © 2002 John Wiley & Sons, Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/162593 |
ISSN | 2023 Impact Factor: 4.6 2023 SCImago Journal Rankings: 1.991 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tan, KCB | en_US |
dc.contributor.author | Chow, WS | en_US |
dc.contributor.author | Ai, VHG | en_US |
dc.contributor.author | Lam, KSL | en_US |
dc.date.accessioned | 2012-09-05T05:21:32Z | - |
dc.date.available | 2012-09-05T05:21:32Z | - |
dc.date.issued | 2002 | en_US |
dc.identifier.citation | Diabetes/Metabolism Research And Reviews, 2002, v. 18 n. 1, p. 71-76 | en_US |
dc.identifier.issn | 1520-7552 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/162593 | - |
dc.description.abstract | Background. Microalbuminuria is associated with dysfunction of the vascular endothelium in patients with diabetes mellitus. The objective of the present study was to determine whether treatment with losartan at a dose sufficient to lower urinary albumin excretion was accompanied by an improvement in endothelial function in type 2 diabetic patients with microalbuminuria. Methods. Endothelial function was measured in 80 type 2 diabetic patients with microalbuminuria and 68 non-diabetic controls using high-resolution vascular ultrasound. The diabetic patients were randomised to receive either losartan 50 mg daily or placebo in a 6-month double-blind study. Urinary albumin excretion and endothelial function were assessed at baseline, 3 and 6 months. Results. Both endothelium-dependent (p < 0.01) and -independent vasodilation (p < 0.01) were significantly impaired in diabetic patients with or without history of hypertension compared to the non-diabetic controls. At baseline, the losartan- and placebo-treated groups were comparable in their clinical characteristics. Blood pressure did not change significantly in either group throughout the study. Urinary mean albumin excretion rate (MAER) decreased in the losartan-treated group (p < 0.01) whereas an increase was observed in the placebo group (p < 0.05). At 6 months, the losartan-treated group had significantly lower MAER than the placebo-treated group [54.5 (58.3) vs 78.5 (100.5) μg/min, p < 0.05; median (interquartile range)]. No significant differences were found in endothelium-dependent or -independent vasodilation. Conclusions. Type 2 diabetic patients with microalbuminuria have impaired endothelium-dependent and -independent vasodilation. Treatment with low-dose losartan is sufficient to reduce microalbuminuria in these patients without alteration in endothelial function and systemic blood pressure. Copyright © 2002 John Wiley & Sons, Ltd. | en_US |
dc.language | eng | en_US |
dc.publisher | John Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/10009394 | en_US |
dc.relation.ispartof | Diabetes/Metabolism Research and Reviews | en_US |
dc.subject | Angiotensin II receptor antagonist | - |
dc.subject | Diabetes mellitus | - |
dc.subject | Endothelial dysfunction | - |
dc.subject | Microalbuminuria | - |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Albuminuria - Drug Therapy | en_US |
dc.subject.mesh | Angiotensin Receptor Antagonists | en_US |
dc.subject.mesh | Diabetes Mellitus, Type 2 - Drug Therapy - Physiopathology | en_US |
dc.subject.mesh | Double-Blind Method | en_US |
dc.subject.mesh | Endothelium, Vascular - Physiopathology | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Losartan - Therapeutic Use | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Placebos | en_US |
dc.subject.mesh | Vasodilation - Drug Effects | en_US |
dc.title | Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria | en_US |
dc.type | Article | en_US |
dc.identifier.email | Tan, KCB:kcbtan@hku.hk | en_US |
dc.identifier.email | Lam, KSL:ksllam@hku.hk | en_US |
dc.identifier.authority | Tan, KCB=rp00402 | en_US |
dc.identifier.authority | Lam, KSL=rp00343 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1002/dmrr.255 | en_US |
dc.identifier.pmid | 11921421 | - |
dc.identifier.scopus | eid_2-s2.0-0036200330 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0036200330&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 18 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 71 | en_US |
dc.identifier.epage | 76 | en_US |
dc.identifier.isi | WOS:000174502000010 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Tan, KCB=8082703100 | en_US |
dc.identifier.scopusauthorid | Chow, WS=7402281153 | en_US |
dc.identifier.scopusauthorid | Ai, VHG=6603342063 | en_US |
dc.identifier.scopusauthorid | Lam, KSL=8082870600 | en_US |
dc.identifier.issnl | 1520-7552 | - |